World News: 20:41 GMT Friday 9th November 2018. [TESARO, Inc. via Globe Newswire via SPi World News]
WASHINGTON Nov 09 2018 GLOBE NEWSWIRE -- TESARO Inc (NASDAQ: TSRO an oncology-focused biopharmaceutical company today presented initial data from the Phase 1 AMBER trial of TSR-022 anti-TIM-3 antibody in combination with TSR-042 anti- PD-1 an...
Globe Newswire: 20:41 GMT Friday 9th November 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.